Isis Pharmaceuticals News

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com . A replay will be available on the Isis Web site within 48 hours and will be archived for a limited time.

There was intensive insider selling in Isis Pharmaceuticals in late April, when the stock was trading above $22. The stock is currently trading at $19.02 or 17.4% below the all time high made in early May.

The Phase 2 study of ISIS-SMNRx is an open-label, multiple-dose, dose-escalation pilot study, which will include eight infants who have been diagnosed with SMA.

Isis Pharmaceuticals is a pharmaceutical company that has had quite a wide range of revenues over the past few quarters.

ISIS Pharmaceuticals traded down 10.23% on Wednesday, hitting $19.65. ISIS Pharmaceuticals has a 1-year low of $7.54 and a 1-year high of $22.30. The stock's 50-day moving average is currently $18.04. The company's market cap is $2.001 billion.

Isis Pharmaceuticals announced today the pricing of an underwritten public offering of 9,000,000 shares of its common stock, offered at a price to the public of $19.00 per share.

Good afternoon and welcome to the ISIS Pharmaceutical's First Quarter 2013 Earnings Conference Call.

Isis Pharmaceuticals, Inc. Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients With Liver Cancer /PRNewswire/ -- Isis Pharmaceuticals, Inc.

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com . Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.

Isis Pharmaceuticals, Inc., a developer of therapeutic drugs inhibiting cell protein synthesis, has initiated a Phase II study of ISIS-SMNRx in infants with spinal muscular atrophy, or SMA.

The firm currently has a "buy" rating on the stock. A number of other analysts have also recently weighed in on ISIS.

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMN[Rx] in infants with spinal muscular atrophy .

At StateoftheMarkets.com, we focus our attention on the top-rated stocks of the market for a few simple reasons.